TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN

  • STATUS
    Recruiting
  • End date
    Sep 28, 2022
  • participants needed
    12
  • sponsor
    University Hospital, Tours
Updated on 7 March 2021

Summary

Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported. The natural history of LMLMs is progressive worsening. LMLMs complex management requires multidisciplinary care in specialised centres, and the "wait-and-see" approach is frequently used. In complicated lymphatic malformations, whatever the location, treatment with oral sirolimus, an mTOR (mammalian Target of Rapamycin) inhibitor, is often used.

Topical sirolimus is a known effective treatment for some cutaneous conditions such as angiofibromas in tuberous sclerosis. Topical applications of sirolimus on the buccal mucosae have been reported in erosive lichen planus and oral pemphigus vulgaris with good tolerance and none to slight detectable blood sirolimus concentrations.

The objective of this study is to evaluate the efficacy and safety of a 1mg/mL sirolimus solution applied once daily on mild to moderate lingual microcystic lymphatic malformation in children and adults after 4, 8, 12, 16, 20 and 24 weeks of treatment as compared to usual care (no treatment).

Description

This is a randomized, open-labelled, multicenter pilot study using an individually randomized stepped wedge design over a 24 weeks period to evaluate topical application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation that do not require systemic treatment, the experimental intervention versus usual care (no treatment), the control condition.

In this design, subjects are included in a cohort where at a randomized time (W0, W4, W8 or W12), they switch from an observational period to the interventional period.

All subjects will be followed for 24 weeks

Details
Condition Lingual Microcystic Lymphatic Malformations
Treatment Sirolimus Oral Liquid Product 1mg/mL
Clinical Study IdentifierNCT04128722
SponsorUniversity Hospital, Tours
Last Modified on7 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 5 yrs?
Gender: Male or Female
Do you have Lingual Microcystic Lymphatic Malformations?
Do you have any of these conditions: Do you have Lingual Microcystic Lymphatic Malformations??
Do you have any of these conditions: Do you have Lingual Microcystic Lymphatic Malformations??
Do you have any of these conditions: Do you have Lingual Microcystic Lymphatic Malformations??
Participants 5 years of age
Lingual microcystic lymphatic malformation that does not require systemic treatment, assessed by clinical examination and head-and-neck MRI imaging prior to study enrolment, with or without underlying syndromic malformation (CLAPO for instance)
Participants covered by or having the rights to social security
Written informed consent obtained from participant and participant's legal representative if participant is under 18
Ability for participant to comply with the requirements of the study

Exclusion Criteria

Patients with a lymphatic malformation requiring a continued background therapy (involving deep organs)
Secondary lymphatic malformations (lymphangiectasia post-radiotherapy, etc)
Previous treatment with systemic or topical mTOR (mammilian target of rapamycin) inhibitors within 12 months before inclusion (half-life of oral sirolimus is 60 days in adults)
Previous treatment with oral or topical steroids within 10 days before inclusion (half-life of corticosteroids is 12-36 hours)
Immunosuppression (immunosuppressive disease or immunosuppressive treatment)
Ongoing neoplasia
Active chronic infectious disease (Hepatitis-B virus, Hepatitis-C virus, HIV, etc)
Local necrosis
Local fungal, viral (herpes simplex virus, varicella zoster virus, etc) or bacterial infection on the site of the LMLM (based on clinical examination)
Known allergy to one of the components of the sirolimus solution
Soy bean or Peanut allergy
Pregnant or breastfeeding women
Women of child-bearing potential (including teenagers) not using a reliable contraceptive method until the end of the study and three month after the end of the study or sirolimus discontinuation
Already involved in another therapeutic trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note